Axon degeneration, a critical process in neurodegeneration, plays a significant role in neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS). IPG023 is an innovative small molecule antagonist that effectively inhibits NADase activation and prevents NAD+ deficiency-induced axonal degeneration; it holds great promise for the treatment of neurodegenerative disorders.
Mechanism of Action
Axon degeneration is an early driver for neurodegeneration in the progression of neurodegenerative diseases. IPG023 is a novel small molecule that blocks the activation of NADase, preventing axon degeneration caused by NAD+ deficiency. IPG023 demonstrates potent inhibition on axonal degeneration induced by direct damage or inflammatory-related neural injuries.